Webinar: A Pharmacogenetic (PGx) Blindspot: The Prevalence and Impact of CYP2D6 Hybrid Alleles

PGx Webinar 2020
PGx Webinar 2020

Date: April 21, 2020

Time: 10am Pacific Time / 7pm CET

Location: Online

Does your PGx detection method have blind spots?

Register Here

CYP2D6 is responsible for the metabolism and elimination of approximately 25% of clinically used medications. Depending on ethnicity, up to 37% of individuals possess a non-functional CYP2D6 hybrid allele. Common CYP2D6 genotyping and copy number detection methods cannot detect these alleles, resulting in pharmacogenetic profile mischaracterization. Dr. Houda Hachad will offer recommendations for overcoming this challenge to achieve a comprehensive CYP2D6 profile and more accurate PGx results.

Questions That Will Be Answered:

  • What is a CYP2D6 hybrid allele?
  • How prevalent are CYP2D6 hybrid alleles across populations?
  • How does missing them affect PGx results?
  • What can be done to ensure accurate CYP2D6 characterization?

Presented By:

Dr. Houda HachadDr. Houda Hachad
Pharm. D, Chief Scientific Officer
Translational Software, Bellevue, Washington

Houda is an entrepreneurial scientist with deep experience in pharmacology and pharmacogenetics. At the University of Washington, she co-developed two knowledge-based technologies, a drug interaction database (DIDB) and a pharmacogenetics database (e-PKGene©). Both leverage revenue-based funding and are widely used by pharmaceutical companies, regulatory agencies, and academic institutions worldwide.

Register Here